Tiragolumab
- Generic Name
- Tiragolumab
- Drug Type
- Biotech
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
- Conditions
- Microsatellite Stable (MSS) Colorectal Cancer (CRC)Metastatic Colorectal Cancer (CRC)Colorectal Cancer Stage IV
- Interventions
- Procedure: Pre-Treatment BiopsyProcedure: On-Treatment Biopsy
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 54
- Registration Number
- NCT06784947
- Locations
- 🇺🇸
Universtiy of Colorado Hospital, Aurora, Colorado, United States
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
- Conditions
- Advanced Solid Malignancies
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT06760481
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT06754501
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures
- Conditions
- Metastatic Cancer LungAdvanced Lung CancerCBNPC Cancer
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 115
- Registration Number
- NCT06713798
- Locations
- 🇫🇷
Centre Hospitalier Cote Basque, Bayonne, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Centre GF Leclerc, Dijon, France
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
- Conditions
- Microsatellite Stable Metastatic Colorectal CancerMetastatic Colorectal CancerColorectal Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy (SBRT)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT06603818
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT06342037
- Locations
- 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Noord-Holland, Netherlands
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06331598
- Locations
- 🇪🇸
Hospital Universitario Virgen; Servicio de Oncologia, Sevilla, Spain
🇪🇸Hospital Universitari Vall dHebron; Oncology, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype
- Interventions
- Procedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingProcedure: Surgical Procedure
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT06328036
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT06267001
- Locations
- 🇨🇳
Ningbo No.2 Hospital, Ningbo, China
🇮🇹Instituto Europeo di Oncologia, Milano, Lombardia, Italy
🇮🇹Azienda U.S.L. 21 - Presidio Ospedaliero S. Spirito; U.O. Di Oncologia Clinica, Casale Monferrato, Piemonte, Italy
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Omico
- Target Recruit Count
- 96
- Registration Number
- NCT06003621
- Locations
- 🇦🇺
Border Medical Oncology Research Unit, Albury, New South Wales, Australia
🇦🇺Ramsay Health Care Australia Pty Ltd trading as The Border Cancer Hospital, Albury, New South Wales, Australia
🇦🇺Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.